Research programme: Creutzfeldt Jakob disease therapies - Serono

Drug Profile

Research programme: Creutzfeldt Jakob disease therapies - Serono

Alternative Names: iPrP13; Prion inhibitory proteins research programme - Axonyx/Serono

Latest Information Update: 28 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University
  • Developer Merck Serono; TorreyPines Therapeutics Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Creutzfeldt-Jakob disease

Most Recent Events

  • 22 Mar 2004 Discontinued - Preclinical for Creutzfeldt-Jakob disease in Switzerland (unspecified route)
  • 23 Oct 2000 Prion inhibitory peptides have been licensed to Serono in Switzerland
  • 21 Jun 2000 Ares-Serono is now called Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top